History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen, or type  diabetes mellitus are eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however,\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, lichen sclerosis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled Type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease that threatens vital organ function, including, but not limited to, systemic lupus erythematosus, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Guillain-Barre syndrome, multiple sclerosis, or glomerulonephritis\r\n* Patients with a prior history of immune related events to anti-CTLA- may be eligible after discussion with the sponsor; however, patients with a history of grade  and  pulmonary, CNS and renal events attributed to anti-CTLA- agents will be excluded\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are permitted provided all of following conditions are met: Rash must cover < % of body surface area; Disease is well controlled at baseline and requires only low-potency topical corticosteroids; No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous  months.
Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations. Rash must cover less than % of body surface area (BSA). Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%). No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).
GENERAL: History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible.\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\r\n* Rash must cover < % of body surface area\r\n* Disease is well controlled at baseline and requires only low-potency topical corticosteroids\r\n* No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous  months
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjgrens syndrome, Bells palsy, Guillain-Barr syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis.\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone, controlled type  diabetes mellitus on a stable insulin regimen are eligible.\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations.\r\n** Rash must cover less than % of body surface area (BSA).\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%).\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).
Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted but patients with psoriasis require a baseline ophthalmologic exam to rule out ocular manifestations; rash must cover less than % of body surface area (BSA) and must be well controlled at baseline and only requiring topical steroids
Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogrens syndrome, Guillain-Barre syndrome, or multiple sclerosis, with the following exception: a. patients with a history of autoimmune hypothyroidism who are on thyroid replacement hormone are eligible for the study; b. patients with controlled type  diabetes mellitus who are on an insulin regimen are eligible for the study; c. patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: i. rash must cover < % of body surface area.; ii. disease is well controlled at baseline and requires only low-potency topical corticosteroids; iii. no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous  months
Acute exacerbations of underlying condition within the last  months (requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis a) Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. b) Patients with controlled Type  diabetes mellitus on a stable insulin regimen may be eligible. c) Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations; rash must cover less than % of body surface area (BSA)
Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%) No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis a. Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. b. Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible. c. Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n* Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations \r\n* Rash must cover less than % of body surface area (BSA)\r\n* Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n* No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barr syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogren syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible; patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible; patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations, rash must cover less than % of body surface area (BSA), disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%), no acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
Patient who have a history or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid-replacement hormone may be eligible\r\n* Patients with controlled Type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA) \r\n** Disease is well controlled at baseline and only requiring low-potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%) \r\n** No acute exacerbations of underlying conditions within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations; Rash must cover less than % of body surface area (BSA); Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%); No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids).
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Note:\r\n** Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible\r\n** Patients with controlled type  diabetes mellitus on a stable insulin regimen are eligible\r\n** Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n*** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n*** Rash must cover less than % of body surface area (BSA)\r\n*** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%)\r\n*** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (i.e. not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled Type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis \r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations \r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency or oral steroids)
Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogrens syndrome, Guillain-Barre syndrome, or multiple sclerosis, with the following exceptions: patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study; patients with controlled type  diabetes mellitus who are on an insulin regimen are eligible for the study; patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\r\n* Rash must cover < % of body surface area\r\n* Disease is well controlled at baseline and requires only low-potency topical corticosteroids\r\n* No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous  months
Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: \r\n* Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations \r\n* Rash must cover less than % of body surface area (BSA) \r\n* Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%) \r\n* No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible; patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible; patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n* Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations \r\n* Rash must cover less than % of body surface area (BSA)\r\n* Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n* No acute exacerbations of underlying condition within the last  months (not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency or oral steroids)
Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n* Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular\r\nmanifestations\r\n* Rash must cover less than % of body surface area (BSA)\r\n* Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, flucinolone .%, desonide .%, aclometasone dipropionate .%)\r\n* No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barr syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
Patients with uncontrolled eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations (patients without ophthalmologic involvement, rash covering < % of the body surface area and requiring only low potency topical steroids, and without exacerbations requiring systemic therapy are eligible)
Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
No acute exacerbations of underlying condition in the last  months (not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, biologics, oral calcineurin inhibitors, high potency oral steroids)
History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegeners granulomatosis, Sjogrens syndrome, Bells palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\r\n* Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible\r\n* Patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible\r\n* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\r\n** Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\r\n** Rash must cover less than % of body surface area (BSA)\r\n** Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone .%, hydrocortisone butyrate .%, fluocinolone .%, desonide .%, alclometasone dipropionate .%)\r\n** No acute exacerbations of underlying condition within the last  months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
